TrialNeurology2019
Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis.
James F Howard et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
159 papers cite itlatest 60 shown
this paperpooled ittrialcites it